Search Results - varghese+john

16 Results

Sort By:

Interactive Systems and Methods for Identifying Target Proteins in Drug Discovery (Case No. 2025-098)

Summary: UCLA researchers from the Department of Electrical and Computer Engineering have developed a novel computational system for target protein identification, enabling integrative drug discovery. Background: Target identification (Target ID) in drug discovery involves the identification and evaluation of protein candidates that could interact...

Published: 10/1/2025 | Inventor(s): Xiang Chen, Youngseung Jeon, Christopher Hwang, Ziwen Li, Jesus Campagna, Varghese John, Whitaker Cohn, Eunice Jun

Keywords(s): AI-driven drug discovery, Alzheimer’s disease target discovery, Bioinformatics software platform, Drug, Drug Discovery, Functional annotation of proteins, High-throughput docking, large language models (LLMs), Ligand-protein docking, Mechanism-of-action prediction, Molecular docking simulation, Multi-criteria decision support, Neurodegenerative disease therapeutics, Pathway-centric drug targeting, personalized medicine, PPI-Comparator, PPI-Explorer, Protein structure prediction, Protein-protein interaction (PPI) analysis, Rational drug design, Retrieval-augmented generation (RAG), Semantic similarity modeling, Small molecule screening, Systems biology interface, Target identification (Target ID), Therapeutic impact modeling, User-guided AI exploration

Category(s): Software & Algorithms, Software & Algorithms > AI Algorithms, Software & Algorithms > Artificial Intelligence & Machine Learning, Software & Algorithms > Digital Health, Life Science Research Tools, Life Science Research Tools > Research Methods, Platforms, Platforms > Drug Delivery

Small molecule sAPPalpha enhancers that inhibit brain p-Tau as a therapeutic for Alzheimer’s Disease (UCLA Case No. 2025-163)

Contact UCLA Technology Development Group to learn more.

Published: 9/18/2025 | Inventor(s): Varghese John, Dongwook Wi, Jesus Campagna

Keywords(s):

Category(s): Therapeutics > CNS and Neurology

Novel MARK4 Inhibitors for Neurodegenerative Disorders (UCLA Case No. 2021-321)

UCLA researchers in the Department of Neurology have developed highly selective inhibitors of MARK4, aiming to revolutionize the treatment landscape for cancer and neurodegenerative disease through precise molecular targeting. BACKGROUND: MARK4 (Microtubule Affinity-Regulating Kinase 4) is a serine/threonine kinase from the AMP-activated protein...

Published: 9/10/2025 | Inventor(s): Varghese John, Jason Hinman, Jesus Campagna

Keywords(s):

Category(s): Therapeutics > CNS and Neurology

Small Molecule Enhancers of Secreted Clusterin (sCLU) as Novel Therapeutics for Alzheimer's Disease (UCLA Case No. 2024-016)

UCLA researchers from the Department of Neurology have identified and synthesized novel small molecules that enhance the levels of secreted clusterin protein, a protein that can targets a significant risk factor for the disease, and offering promising potential for the treatment of Alzheimer’s disease. BACKGROUND: Alzheimer’s disease (AD)...

Published: 7/17/2025 | Inventor(s): Varghese John

Keywords(s):

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Stem Cells And Regenerative Medicine

Synthetic Exosomes (SE) for CNS Delivery of CRISPR for Gene Editing in Brain Disorders (UCLA Case No. 2021-363)

UCLA researchers from the Department of Neurology have developed synthetic exosomes, a novel delivery technology capable of transporting gene-editing tools and therapeutics across the blood-brain barrier, with successful applications in repairing Alzheimer’s-related mutations and delivering proteins, antibodies, and drugs. BACKGROUND: The emergence...

Published: 7/17/2025 | Inventor(s): Varghese John

Keywords(s): Alzheimers disease, CRISPR, delivery system, exosome, Nanotechnology, nanovesicles, synthetic biology

Category(s): Life Science Research Tools > Microfluidics And Mems, Materials > Nanotechnology, Platforms > Drug Delivery, Therapeutics > Gene Therapy And Editing, Therapeutics > CNS and Neurology

Salivary Exosome (NSEV) Analysis to Elucidate Intercellular Signaling Events that Precede Pilot Fatigue (UCLA Case No. 2021-172)

Researchers at UCLA’s Department of Neurology and Drug Discovery Lab have identified a novel set of biomarkers that change based on levels of Cognitive Fatigue (CF). These biomarkers can be used to non-invasively predict and assess levels of cognitive fatigue. BACKGROUND: Cognitive fatigue (CF) is an important factor in the efficiency and safety...

Published: 7/17/2025 | Inventor(s): Bruce Teter, Whitaker Cohn, Varghese John

Keywords(s): biomarkers, cognitive fatigue, exosome, noninvasive, non-invasive

Category(s): Diagnostic Markers > Targets And Assays

Small Molecule Humanin Mimetics and Enhancers That Normalize Neuronal p-AKT as Novel Therapeutics for Alzheimer's Disease (UCLA Case No. 2023-230)

UCLA researchers in the Department of Neurology have discovered novel small molecule humanin mimetics for the treatment of Alzheimer's disease and other chronic conditions with dysregulated p-Akt. BACKGROUND: Alzheimer’s disease (AD) is the most common form of dementia accounting for 60-70% of all cases. Nearly 7 million Americans are living...

Published: 7/17/2025 | Inventor(s): Varghese John

Keywords(s): Alzheimers disease, Cardiovascular, Cardiovascular Disease, Dementia, diabetes, mimetics, pAKT signaling, small molecules

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Cardiovascular

Novel Compounds Targeting APOE4 That Enhance Brain SIRT1 Levels and Target Novel Mechanism of Action (UCLA Cases 2020-832, 2025-277)

Researchers at UCLA's Drug Discovery Lab and Department of Chemistry have developed new chemical entity (NCE) analogs of A03, which together form a new class of compounds that target apolipoprotein E4 (ApoE4)-mediated deficits in the tau deacetylase enzyme, sirtuin 1 (SirT1). These NCEs provide an opportunity for novel therapeutic development in Alzheimer's...

Published: 9/18/2025 | Inventor(s): Varghese John, Jesus Campagna, Michael Jung

Keywords(s): Brain

Category(s): Therapeutics

2020-408: sAPPalpha Targeted Therapeutics for Alzheimer’s Disease

UCLA researchers from the Department of Neurology have developed a novel application of two compounds that target the upstream formation of toxic amyloid-beta oligomers for the effective treatment of Alzheimer’s disease. BACKGROUND: Alzheimer’s Disease (AD) is the most common age-related neurodegenerative disorder currently affecting ~6...

Published: 7/17/2025 | Inventor(s): Varghese John, Sujyoti Chandra

Keywords(s): Chemical, Cns, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > CNS and Neurology

2018-200 AMYLOID PRECURSOR PROTEIN-SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER’S DISEASE

Amyloid Precursor Protein-Selective BACE Inhibitors for Alzheimer’s DiseaseSUMMARYUCLA researchers in the Department of Neurology have invented novel Alzheimer’s disease (AD) therapeutics that are selective for BACE1 inhibition and cleavage of the amyloid precursor protein (APP) substrate.BACKGROUNDAlzheimer’s disease is characterized...

Published: 12/2/2025 | Inventor(s): Barbara Jagodzinska, Varghese John, Patricia Spilman, Jesus Campagna

Keywords(s): Cns, Life Science Research Tools, Medical Devices and Materials, Targets And Assays, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Diagnostic Markers > Targets And Assays, Medical Devices, Therapeutics, Therapeutics > CNS and Neurology

1 2